Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 19;11(20):3294. doi: 10.3390/cells11203294

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Regulation by USP7 of the chemosensitivity of chemo-drug resistant TNBC. (A) Analysis of growth of MDA-MB-231-DoxR-USP7-silencing (upper) and MDA-MB-231-PtxR-USP7-silencing (lower) cells treated with various doses of doxorubicin and paclitaxel, assessed using colony formation assays. (B) Quantitative analysis for colony formation assays in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells with USP7 suppression under treatment of doxorubicin and paclitaxel, respectively. (C) Analysis of the viability in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells with USP7 suppression treated with serial doses of doxorubicin and paclitaxel, respectively, performing MTT assays. (D) Analysis of the proliferative activity of MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells with USP7 suppression treated with doxorubicin or paclitaxel for 24, 48, or 72 h, performing MTT assays. (E) Analysis of apoptosis in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells with USP7 suppression treated with serial doses of doxorubicin or paclitaxel, assessed by Annexin V-dependent flow cytometry assays. (F) Quantitative analysis of apoptotic levels of serial doses of doxorubicin-treated MDA-MB-231-DoxR (left) and paclitaxel-treated MDA-MB-231-PtxR (right) with USP7 suppression. (G) Protein levels of cleaved caspase family members in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells with USP7 suppression, treated with serial doses of doxorubicin or paclitaxel, assessed by western blot analysis using specific antibodies. (H) Analysis of MMP for MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells with USP7 suppression, treated with serial doses of doxorubicin or paclitaxel, assessed using flow cytometry assays. (I) Quantitative analysis for total depolarized levels of MMP in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) with USP7 suppression under treatment of serial doses of doxorubicin and paclitaxel, respectively. (J) Bcl family member expression in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells with USP7 suppression under treatment of serial doses of doxorubicin or paclitaxel, by western blot analysis with specific antibodies. Data are represented as the mean ± SEM for biological triplicate experiments. * p < 0.05, compared with cells with steady concentration of doxorubicin and paclitaxel, respectively.

Regulation by USP7 of the chemosensitivity of chemo-drug resistant TNBC. (A) Analysis of growth of MDA-MB-231-DoxR-USP7-silencing (upper) and MDA-MB-231-PtxR-USP7-silencing (lower) cells treated with various doses of doxorubicin and paclitaxel, assessed using colony formation assays. (B) Quantitative analysis for colony formation assays in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells with USP7 suppression under treatment of doxorubicin and paclitaxel, respectively. (C) Analysis of the viability in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells with USP7 suppression treated with serial doses of doxorubicin and paclitaxel, respectively, performing MTT assays. (D) Analysis of the proliferative activity of MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells with USP7 suppression treated with doxorubicin or paclitaxel for 24, 48, or 72 h, performing MTT assays. (E) Analysis of apoptosis in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells with USP7 suppression treated with serial doses of doxorubicin or paclitaxel, assessed by Annexin V-dependent flow cytometry assays. (F) Quantitative analysis of apoptotic levels of serial doses of doxorubicin-treated MDA-MB-231-DoxR (left) and paclitaxel-treated MDA-MB-231-PtxR (right) with USP7 suppression. (G) Protein levels of cleaved caspase family members in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells with USP7 suppression, treated with serial doses of doxorubicin or paclitaxel, assessed by western blot analysis using specific antibodies. (H) Analysis of MMP for MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells with USP7 suppression, treated with serial doses of doxorubicin or paclitaxel, assessed using flow cytometry assays. (I) Quantitative analysis for total depolarized levels of MMP in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) with USP7 suppression under treatment of serial doses of doxorubicin and paclitaxel, respectively. (J) Bcl family member expression in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells with USP7 suppression under treatment of serial doses of doxorubicin or paclitaxel, by western blot analysis with specific antibodies. Data are represented as the mean ± SEM for biological triplicate experiments. * p < 0.05, compared with cells with steady concentration of doxorubicin and paclitaxel, respectively.